Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, Cantor Fitzgerald boosted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research note […]
12 Oct 05:19 · The Markets Daily